NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuBase Therapeutics is a pre-clinical stage biopharmaceutical company that develops gene silencing therapies with its synthetic antisense oligonucleotides. It also provides a platform that focuses on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy, and Familial Parkinson's Disease, among others.

PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues). For this research, the Healthcare Company will evaluate NeuBase's PATrOL™ technology for three monogenic genetic diseases.

NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company

NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing.

NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce

PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Company's board of directors and management team, includes several initiatives aimed at streamlining the organization, reducing operating expenses, preserving capital, and creating long-term shareholder value.

NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan's 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022.

NeuBase to Participate at Chardan's 6th Annual Genetic Medicines Conference

NeuBase (NBSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NeuBase (NBSE) Moves to Buy: Rationale Behind the Upgrade

PITTSBURGH and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended June 30, 2022, and other recent developments.

NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced the promotion of William (Bill) Mann, Ph.D. to President of the Company, effective immediately. Dr. Mann will also continue to serve as NeuBase's Chief Operating Officer.

NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO

PITTSBURGH and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that company management will present a corporate overview at the Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.

NeuBase to Participate at the Jefferies Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended March 31, 2022, and other recent developments.

NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced two abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy (“ASGCT”) 25th Annual Meeting, taking place virtually and in person in Washington, D.C., May 16-19, 2022.

NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

PITTSBURGH and CAMBRIDGE, Mass., March 13, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). These data are being presented in poster and oral presentations at the 2022 MDA Clinical & Scientific Conference, which is taking place virtually and in-person in Nashville, Tennessee from March 13-16, 2022. These data will also be presented at the RNA Leaders World Congress in Basel on March 17th.

NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that company management will participate in a fireside chat and will be available for one-on-one meetings at Oppenheimer's 32nd Annual Healthcare Conference being held virtually March 15 – 17, 2022.

NeuBase to Present at Oppenheimer's 32nd Annual Healthcare Conference

PITTSBURGH and CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2021, and other recent developments.

NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies.

NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

PITTSBURGH and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Eric J. Ende, M.D., to the Company's Board of Directors. Dr. Ende has nearly 25 years of experience in advising biotechnology and life sciences companies to optimize corporate strategy and structure and maximize shareholder value.

NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors

PITTSBURGH and CAMBRIDGE, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2021, and other recent developments.

NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18.

NeuBase to Present at the Jefferies London Healthcare Conference

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5.

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23.

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 to 15.

NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference

PITTSBURGH, Aug. 12, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three- and nine-month periods ended June 30, 2021.

NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights

PITTSBURGH, June 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced positive new data and program updates for its development pipeline of PATrOL-enabled genetic medicines.

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry

NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer

Expansion of management team to support the Company's advancement of its first drug candidate into clinical trials next year and growth of therapeutic pipeline Expansion of management team to support the Company's advancement of its first drug candidate into clinical trials next year and growth of therapeutic pipeline

NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat  at 11:30 a.m. ET on May 19

News for NeuBase Therapeutics Inc Stock (NBSE)